Drug Database
KH

KH-741 (KH 741 / KH741)

✓ Approved

Chengdu Kanghong Pharmaceutical · 小分子 · 小分子

什么是 KH-741?

KH-741 是一种小分子,由Chengdu Kanghong Pharmaceutical研发。该药已获批,用于治疗相关适应症,给药途径:Unknown。

药物档案

商品名KH 741, KH741
公司Chengdu Kanghong Pharmaceutical
药物类别小分子
给药途径Unknown
状态Approved

治疗适应症

KH-741 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Psychiatric disordersBipolar I disorder✓ Approved

相关研究文献

PubMedBMC plant biology2026-11-19

Integrated physiological, transcriptomic and metabolomic analyses characterize treatment-associated autumn shoot self-pruning and maturation in Wogan mandarin.

Li Guoguo G, Chen Qiuyou Q, Bei Xuejun X, Luo Yin Y et al.

Autumn shoot maturation is important for citrus canopy management and subsequent reproductive development. We compared five foliar treatments but interpret their effects as treatment-specific because the salts were not equimolar and KH₂PO₄ supplied both K and P. Water (CK), 0.3% (w/v) KNO₃, 0.3% KH₂PO₄, 0.3% K₂SO₄ and a seaweed-polysaccharide product were applied twice to 15 three-year-old Wogan mandarin trees (three trees per treatment). Under an exploratory equal-weight framework, KH₂PO₄ had the highest integrated score (0.858) and remained first in all 11 leave-one-indicator-out analyses. Longitudinal mixed models detected treatment-by-linear-time interactions for shoot length, shoot diameter, internode length, leaf number, leaf width and leaf thickness, but not for self-pruning rate or SPAD. RNA-seq and untargeted LC-MS profiling of CK and KH₂PO₄ leaves and stems showed tissue- and stage-dependent responses. The broad VIP > 1 and P < 0.05 metabolite set was largest at 3 d (554 leaf and 357 stem features), whereas only 31 leaf and one stem feature at 3 d met VIP > 1 and BH q < 0.05; the remaining six comparisons had none. Co-expression, putative PPI and pathway analyses prioritized lignin-, hormone- and redox-related candidates. qRT-PCR of nine genes detected 19 FDR-significant tissue-time responses and supported several key RNA-seq expression patterns. Foliar KH₂PO₄ was associated with high leaf K, low Na, carbon-osmotic adjustment, redox stabilization and lignin-related transcription. These data identify treatment-associated candidate pathways and genes rather than a K-specific, P-specific or causal mechanism.

PMID 43052743
阅读全文 →
PubMedNature communications2026-11-18

Alkali hydrides catalyze hydrogenolysis of polystyrene to alkylbenzenes under mild conditions.

Li Zhao Z, Cai Yongli Y, Tan Khai C KC, Liu Bing B et al.

This study introduces a highly efficient, transition-metal-free method for upcycling polystyrene (PS) waste using alkali metal hydrides, specifically KH, as a catalyst. Operating under mild conditions (130 °C, 1 bar H₂, 3 hours), KH achieves an impressive 93.2% yield of gaseous products and alkylbenzenes, with 95.8% selectivity toward alkylbenzenes. The production rate of 313.3 mmolcarbon/gKH/h is approximately 2.6 times higher than noble-metal catalysts operating at much higher temperatures (280 °C). This versatile approach is effective on diverse real-life PS waste. Mechanistically, depolymerization is driven by a synergy between direct hydride-induced Hδ+(C) abstraction and K+···π interactions with adjacent phenyl rings. This interaction elongates the C(sp³)-C(sp³) bonds, facilitating targeted cleavage into alkylbenzenes. Ultimately, this work establishes hydride catalysis as an energy-efficient platform for plastic depolymerization, providing crucial insights for designing mild-condition catalysts to address the global plastic waste crisis.

PMID 43045705
阅读全文 →
PubMedBMJ (Clinical research ed.)2026-11-18

Effect of intrapartum hyoscine butylbromide and sodium bicarbonate on spontaneous vaginal birth in nulliparous women after induction of labour (SAINT): multicentre randomised placebo controlled factorial trial.

Michelsen Trond Melbye TM, Leeves Lisa Tangnes LT, Solhoff Aslak Vimme AV, Nilsen Nina Gunnes NG et al.

To determine whether intrapartum hyoscine butylbromide, sodium bicarbonate, and their combination increase the rate of spontaneous vaginal birth in nulliparous women undergoing induction of labour. Multicentre, randomised, double blind, placebo controlled, 2×2 factorial phase 3 trial (SAINT). 11 Norwegian hospitals providing comprehensive obstetric care. Nulliparous women aged 18-50 years with a singleton live fetus in cephalic presentation at term with an indication for induction of labour. Participants were randomly assigned (1:1:1:1) to oral sodium bicarbonate (4×1 g per dose) plus intravenous hyoscine butylbromide (20 mg per dose), oral sodium bicarbonate plus intravenous placebo, oral placebo plus intravenous hyoscine butylbromide, or double placebo. The investigational medicinal product was administered at the onset of active labour and repeated every four hours to a maximum of three doses. Spontaneous vaginal birth (no instrumental or caesarean delivery). Between 4 January 2023 and 29 January 2025, 3094 nulliparous women were randomised, and 2963 comprised the full analysis set. Spontaneous vaginal birth occurred in 57% (422/741) in the bicarbonate plus hyoscine butylbromide arm, 61% (445/734) in the bicarbonate arm, 61% (449/741) in the hyoscine butylbromide arm, and 56% (422/747) in the double placebo arm. Marginal risk differences for spontaneous vaginal birth compared with double placebo were -0.2 (95% confidence interval -5.1 to 4.7; P=0.93) percentage points for combined treatment, 3.1 (-1.7 to 8.0; P=0.21) percentage points for bicarbonate, and 4.0 (-0.8 to 8.9; P=0.10) percentage points for hyoscine butylbromide. Serious adverse events were similar between groups, and no treatment related serious morbidity or deaths were observed. No clear evidence was found that intrapartum hyoscine butylbromide, sodium bicarbonate, or their combination increased spontaneous vaginal birth compared with placebo. Although small beneficial effects cannot be excluded, the findings do not support routine intrapartum use of either agent to facilitate spontaneous vaginal birth after induction of labour. European Clinical Trials Database (EudraCT; 2021-000392-37); EU Clinical Trials Information System (CTIS; EU CT number 2024-511848-55-00); ClinicalTrials.gov (NCT05719467).

PMID 43051685
阅读全文 →
PubMedFrontiers in plant science2026-11-18

FLOWERING LOCUS K and C-terminal domain phosphatase-like 1 cooperate to repress FLOWERING LOCUS C and promote flowering in Arabidopsis thaliana.

Rodríguez-Cazorla Encarnación E, Ramos Sara S, Monfort Elena E, Candela Héctor H et al.

Successful plant reproduction largely relies on the timely transition to flowering, a developmental switch orchestrated by intertwined genetic regulatory networks that integrate internal and environmental cues. In Arabidopsis thaliana, a central regulator of this process is the floral repressor FLOWERING LOCUS C (FLC), whose expression is exquisitely modulated by components of the autonomous pathway through transcriptional and co-transcriptional mechanisms. The KH-domain protein FLOWERING LOCUS K (FLK) downregulates FLC splicing. Consequently, flk mutants flower late because of high FLC expression levels. In this study, we show that FLK functionally interacts with C-TERMINAL DOMAIN PHOSPHATASE-LIKE 1 (CPL1) to promote flowering. CPL1 dephosphorylates the C-terminal domain (CTD) of RNA polymerase II (RNAP II), contributing to the repression of FLC transcription. In line with this, cpl1 mutants flower moderately late due to a mild increase in FLC levels. Our genetic and molecular analyses indicate that the lack of CPL1 synergistically enhances FLC expression and flowering time in the flk background. The physical interaction between FLK and CPL1 might support this scenario. We also found that, in addition to flowering, FLK and CPL1 interact in response to abiotic stress. These observations are consistent with our transcriptomic analysis and suggest the existence of additional common target genes beyond FLC. Our findings offer new perspectives on FLC co-transcriptional regulation, and the coordination between flowering and stress responses.

PMID 43048531
阅读全文 →
PubMedFrontiers in immunology2026-11-18

Mitochondrial quality control and intestinal barrier dysfunction in inflammatory bowel disease: knowledge mapping and translational perspectives on traditional Chinese medicine-derived bioactive compounds.

Mao Yuanting Y, Zhou Guopei G, Li Xiaojian X, Zhang Leichang L et al.

Inflammatory bowel disease is a chronic relapsing intestinal disorder characterized by intestinal barrier dysfunction, gut microbiota dysbiosis, mitochondrial impairment, and mucosal immune imbalance. Mitochondrial quality control links epithelial energy metabolism, oxidative stress, mitophagy, inflammasome activation, and barrier homeostasis. Traditional Chinese medicine-derived bioactive compounds and natural products may provide multi-target regulatory advantages, yet the knowledge structure and translational trajectory remain unclear. This study aimed to map the landscape of mitochondrial quality control and intestinal barrier dysfunction in inflammatory bowel disease and clarify the translational potential of traditional Chinese medicine-derived bioactive compounds and natural products targeting mitochondrial-related mechanisms. Literature was retrieved from the Web of Science Core Collection and PubMed from January 1, 2000 to May 31, 2026. A two-stage bibliometric and knowledge-mapping analysis was conducted. Stage 1 focused on mitochondrial quality control and intestinal barrier dysfunction, whereas Stage 2 focused on traditional Chinese medicine-derived bioactive compounds and natural products targeting mitochondrial-related mechanisms. Publication trends, countries/regions, institutions, authors, journals, keywords, and co-cited references were analyzed. Stage 1 identified 909 Web of Science Core Collection records and 741 PubMed records, with publication output increasing after 2020 and reaching 198 records in 2025. This field involved 51 countries/regions, 1,128 institutions, and 5,574 authors, with the United States, China, and Germany as leading contributors. Its intellectual base centered on NOD2/CARD15, ATG16L1, autophagy, Paneth cell dysfunction, antimicrobial peptide deficiency, oxidative phosphorylation, gut microbiota, and epithelial defense. Stage 2 expanded rapidly, increasing from 32 records in 2020 to 121 in 2025. This direction involved 42 countries/regions, 592 institutions, and 2,731 authors, with China occupying a dominant position. Research hotspots shifted from pharmacodynamic evaluation and experimental colitis models toward mitophagy, oxidative stress, NF-κB/NLRP3 inflammasome signaling, AMPK/mTOR signaling, SIRT1 activation, gut microbiota regulation, and barrier repair. Mitochondrial quality control is becoming a central framework for understanding inflammatory bowel disease. Current hotspots indicate a shift toward an integrated regulatory network involving mitochondria, immune responses, gut microbiota, and intestinal barrier function. Future frontiers should focus on causal validation of mitophagy-related pathways, identification of patient subgroups with abnormal mitochondrial quality control, and development of multi-target interventions to restore mucosal immune balance and barrier homeostasis. Traditional Chinese medicine-derived bioactive compounds and natural products may be valuable because their multi-pathway regulatory properties are consistent with the complex pathobiology of inflammatory bowel disease.

PMID 43047770
阅读全文 →
PubMedInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2026-11-15

Massive subchorionic thrombohematoma (Breus' mole): A nationwide retrospective study in Japan.

Nagao Takeshi T, Ito Yuki Y, Suemitsu Tokumasa T, Hasegawa Akihiro A et al.

To estimate the incidence, diagnostic features, and perinatal outcomes of massive subchorionic thrombohematoma (MST) in Japan. This nationwide multicenter retrospective study (2018-2023) analyzed confirmed cases of MST, defined as a laminated hematoma with a maximum thickness ≥1 cm. Maternal characteristics, sonographic patterns, and perinatal complications were evaluated. Of 346 741 deliveries across 87 tertiary perinatal centers, 69 pathologically confirmed MST cases were identified at 27 centers, yielding an incidence of 0.019% (69/346 741). Median maternal age was 33 years and body mass index (BMI) was 21.1. Chronic hypertension was present in 8.7% (6/69). Diagnoses occurred antenatally in 81.2% (56/69) and postpartum in 18.8% (13/69). Ultrasound findings included placentomegaly or a placental mass with variable echogenicity. During follow-up, echogenicity changed in 28% of cases and lesion size in 57%. Perinatal outcomes included induced abortion in 13.0% (9/69), miscarriage before 22 weeks in 5.8% (4/69), stillbirth in 7.2% (5/69), preterm birth in 52.2% (36/69), and term delivery in 21.7% (15/69). Among preterm births, one neonatal death and two infant deaths occurred. After excluding induced abortion and miscarriage before 22 weeks, small-for-gestational-age status was present in 53.6% (30/56) of infants, pre-eclampsia occurred in 16.1% (9/56), and preterm premature rupture of membranes occurred in 23.2% (13/56). Neonatal intensive care unit admission was required for 82.4% (42/51) of live births. MST is a rare but high-risk placental disorder associated with miscarriage, stillbirth, preterm birth, impaired fetal growth, and pre-eclampsia. When MST is suspected antenatally, close maternal and fetal surveillance is warranted.

PMID 43032933
阅读全文 →

注册免费账户还可查看另外 8013 篇文献

免费注册查看全部文献 →

了解更多KH-741